



CERTIFICATE OF MAILING

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED  
WITH THE UNITED STATES POSTAL SERVICE WITH SUFFICIENT  
POSTAGE AS FIRST-CLASS MAIL IN AN ENVELOPE ADDRESSED TO:  
COMMISSIONER FOR PATENTS, WASHINGTON, D.C. 20231,

ON April 22, 2003

*Kathleen L. Leavens*  
*April 22, 2003*  
\_\_\_\_\_  
DATE

Attorney Docket No.: P32286

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Blackler, et al. April 22, 2003  
Appln. No.: 10/019,355 Group Art Unit: 1625  
Filed: March 22, 2002 Examiner: B.M. Robinson  
For: THIAZOLIDINEDIONE DERIVATIVE AND ITS USE AS ANTIDIABETIC

Commissioner for Patents  
Washington, D.C. 20231

RECEIVED  
APR 25 2003  
TECH CENTER 1600/2000  
1625

11/B+Prior  
Art w/dt  
c/m  
4-22-03  
Bet  
5-30-03

AMENDMENT AND INFORMATION DISCLOSURE STATEMENT

Sir:

In response to the Office Action dated October 22, 2002, please amend the above-identified application as follows:

In the claims:

Kindly cancel claims 1-8 and 12, without prejudice or disclaimer.

Please add claims 13-23 as follows:

13. (New) A compound, 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, hydrochloride dihydrate, wherein said compound provides at least one of:

B1

(i) an infrared spectrum containing peaks at 3392, 2739, 1751, 1325 and 713 cm<sup>-1</sup>; and

(ii) an X-ray powder diffraction pattern containing peaks at 9.1, 12.0, 15.7, 16.3 and 19.8 °2θ.

04/24/2003 GWORDOF1 00000034 192570 10019355

01 FC:1806 180.00 CH

04/24/2003 GWORDOF1 00000034 192570 10019355

03 FC:1202 36.00 CH